Oruka Therapeutics, Inc. · NASDAQ:ORKA

Oruka Therapeutics — Variagenics — Merger or Acquisition (January 2003)

14 slides from Oruka Therapeutics's merger presentation, Jan 28, 2003

  1. Slide 1: Nuvelo Hyseq/Variagenics Merger January 2003

    Nuvelo Hyseq/Variagenics Merger January 2003

  2. Slide 2: Safe Harbor Statement

    Statements included in this talk which are not historical in nature, including those relating to Hyseq's proposed merger with VARIAGENICS and Hyseq's future business prospects, are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Re

  3. Slide 3: Nuvelo Overview

    Nuvelo Overview

  4. Slide 4: Opportunity

    Nuvelo Opportunity Nuvelo will maximize excellent cash position and experienced management to develop high-value products Well capitalized Highly efficient organization Veteran Management and Board of Directors Alfimeprase Secreted Proteins Cancer Immunotherapeutics Molecular Diagnostics Amgen Kirin

  5. Slide 5: Structure

    Nuvelo Structure Begin trading with new Nasdaq symbol, NUVO, on Feb. 3, 2003 7 Board Members Dr. George Rathmann to serve as chairman Dr. Ted Love to serve as President, CEO and board member 2 additional directors from Hyseq Richard Brewer, Mary Pendergast 3 directors from Variagenics Philippe Chamb

  6. Slide 6: Alfimeprase

    Alfimeprase

  7. Slide 7: Alfimeprase: Near-term Product Opportunity

    Alfimeprase: Near-term Product Opportunity World class partner, Amgen Novel acting thrombolytic Targeting peripheral vascular disease Compelling pre-clinical data-faster & more consistent clot lysis Clinical Status Currently in Phase I trials Plan to initiate Phase II trials in 1H'03 Market large an

  8. Slide 8: Cancer Diagnostics

    Cancer Diagnostics

  9. Slide 9: Cancer Diagnostics

    Cancer Diagnostics Development of novel, high value molecular diagnostic products for colorectal cancer First trial: Markers for 5-FU Toxicity Initiated in September 2002 Results expected late Q2 '03 Novartis partnership Building experience in oncology molecular diagnostics Short-term R&D funding, l

  10. Slide 10: Strong Partnerships & Expanded Partnering Opportunities

    Strong Partnerships & Expanded Partnering Opportunities

  11. Slide 11: Expanded Partnering Opportunities

    Expanded Partnering Opportunities Secreted Gene Collection Cancer Immunotherapeutics Antibody Target Program Small Molecule Targets R&D Capabilities Bioinformatics and Sequence Analysis cDNA Cloning and Expression Cell Based Assays Molecular Epidemiology Programs Pharmacogenomic Association Studies

  12. Slide 12: Near-Term Milestones

    Near-Term Milestones Development Programs Initiate alfimeprase Phase II program in the first half of 2003 Identify additional clinical candidates from Hyseq genes Early results from 5FU toxicity association studies in Q2 2003 Progress and partner cancer immunotherapeutic programs Continue to build &

  13. Slide 13: Highlights

    Nuvelo Highlights Maximizing excellent cash position and experienced management team to support development of novel products Alfimeprase, near-term product opportunity currently in Phase I clinical trials Cancer diagnostics Robust drug discovery program (cancer immunotherapeutics, secreted proteins

  14. Slide 14: Additional Information

    Nuvelo Nasdaq: NUVO Additional Information In connection with the proposed merger, Hyseq and Variagenics have filed a joint proxy statement/prospectus and supplement to joint proxy statement/prospectus with the Securities and Exchange Commission (SEC). INVESTORS AND SECURITY HOLDERS ARE URGED TO REA

Variagenics — Merger or Acquisition (January 2003) on 6ix